IP Library › Granted Patent US 12,265,078
Granted Patent B2
US 12,265,078 · App. 17/041,912 · Granted Apr 1, 2025

Modeling neurological disorders and ataxias with cardiac dysfunction using bioengineered heart tissues

Inventors: Ronald A. Li (Hong Kong, CN); Kevin D. Costa (New York, NY)
Assignee: NOVOHEART INTERNATIONAL LIMITED
G01N33/5044C12N5/0657G01N33/5082G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,265,078
App. No.
17/041,912
Granted
Apr 1, 2025
Kind
B2
Abstract

A system for screening compounds for therapeutic cardiac effects in the cells, tissues and organoids ( 1 ) of patients having diseases such as neurological diseases or disorders with significant cardiac comorbidities. The system comprises a medical device apparatus that can be suitable for a single-tier screen for cardio-active compounds that comprises a human ventricular cardiac anisotropic sheet (hvCAS) and human ventricular cardiac tissue strip (hvCTS), a two-tier system further comprising human ventricular cardiac organoid chamber (hvCOC) ( 20 ), or a three-tier system still further comprising a medical device comprising multiple organoids ( 20 ), which include tissues or organoids ( 1 ) of the same or different type (e.g., heart, liver, pancreas, kidney). Another aspect of the disclosure is the methods suitable for use with the systems, comprising screens for identifying compounds having cardiac effects on cells, tissues or organoids ( 1 ) of patients having a non-cardiac disease exhibiting a cardiac effect, such as neurological diseases. The methods are further useful in assessing the toxicity of compounds to various cells, tissues or organoids ( 1 ) of such patients.

Claims (40)

1. A system for screening a compound for a cardiac effect on cardiomyocytes of a diseased organism or engineered cardiomyocytes comprising:

(a) a screening apparatus comprising:

(i) a biocompatible gel comprising a plurality of cardiomyocytes of a diseased organism or a plurality of engineered cardiomyocytes;

(ii) a biocompatible support apparatus for suspending the biocompatible gel, wherein the biocompatible gel and biocompatible support apparatus form a cardiac tissue strip comprising cardiomyocytes of a diseased organism or engineered cardiomyocytes;

(iii) a detection device for detecting movement of the biocompatible gel; and

(iv) an electrical power source for applying an electrical pacing stimulus to the biocompatible gel; and

(b) a second-stage screening apparatus comprising:

(i) at least one organoid module comprising at least one organoid cartridge, wherein the organoid cartridge comprises a media inlet, a media outlet, and at least one wall compatible with an external detection device, wherein each organoid cartridge comprises a cardiomyocyte or a plurality of cardiomyocytes of a diseased organism or an engineered cardiomyocyte or a plurality of engineered cardiomyocytes, and wherein at least one organoid cartridge comprises cardiomyocytes of a diseased organism or engineered cardiomyocytes; and

(ii) a detection device for observing the monitored biological development of the cardiomyocytes of the diseased organism or the engineered cardiomyocytes in each organoid cartridge.

2. The system of claim 1 , wherein the second-stage screening apparatus further comprises a mirror arrangement for simultaneous monitoring of any biological development of the cardiomyocytes of a diseased organism or engineered cardiomyocytes in each organoid cartridge.

3. The system of claim 1 , wherein the cardiomyocytes are human cardiomyocytes.

4. The system of claim 1 , wherein the cardiomyocytes are engineered cardiomyocytes or are derived from a patient having Friedreich's ataxia (FRDA), Kearns-Sayre syndrome, carbohydrate-deficient glycoprotein syndrome type Ia, spinocerebellar ataxia, Wilson disease, Dandy-Walker syndrome, dilated cardiomyopathy with ataxia, Leigh disease, MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), or MERRF (myoclonic epilepsy with ragged red fibers).

5. The system of claim 4 , wherein the cardiomyocytes are engineered to have low FXN expression or are derived from a patient with Friedreich's ataxia (FRDA).

6. The system of claim 1 , wherein the biocompatible gel comprises matrigel or a combination of matrigel and collagen.

7. The system of claim 1 , wherein the support apparatus is at least two vertical support members made of polydimethylsiloxane.

8. The system of claim 1 , wherein the second-stage screening apparatus further comprises a temperature control element, a light source, a module access port, or any combination thereof.

9. The system of claim 1 , wherein the second-stage screening apparatus further comprises a data processor in electronic communication with the detection device, a temperature control element, a light source, a module access port or any combination thereof.

10. The system of claim 1 , wherein the detection device is a digital camera, at least one pressure transducer, or a combination of a digital camera and at least one pressure transducer.

11. The system of claim 1 comprising a plurality of organoid modules.

12. The system of claim 1 further comprising an interconnected fluid exchange network, wherein the network comprises a plurality of fluid lines, a plurality of valves, at least one pump, and at least one fluid tank.

13. The system of claim 12 further comprising a port for introduction of a compound.

14. The system of claim 12 wherein the fluid is media.

15. The system according to claim 1 further comprising a gas pressure controller.

16. The system according to claim 1 further comprising a drug perfusion apparatus for delivery of a compound to the cardiomyocytes.

17. The system of claim 1 , wherein the detection device is a high-speed camera.

18. The system of claim 1 , wherein the mirror arrangement of the second-stage screening apparatus comprises at least one pyramidal mirror.

19. The system of claim 1 , wherein the screening apparatus further comprises an electrode in adjustable relation to the cardiomyocytes in at least one organoid cartridge.

20. The system of claim 12 , wherein the interconnected fluid exchange network comprises fluid communication between at least two organoid cartridges.

21. A system for screening a compound for a cardiac effect on cardiomyocytes of a diseased organism or engineered cardiomyocytes comprising:

(a) a screening device comprising:

(i) an anisotropic layer of cardiac cells on a microfabricated substrate;

(ii) an electrical power source for stimulating the anisotropic layer of cells at one or more points; and

(iii) a detection device for detecting an electrical signal propagation in the anisotropic layer of cells; and

(b) a second-stage screening apparatus comprising:

(i) at least one organoid module comprising at least one organoid cartridge, wherein the organoid cartridge comprises a media inlet, a media outlet, and at least one wall compatible with an external detection device, wherein each organoid cartridge comprises a cardiomyocyte or a plurality of cardiomyocytes of a diseased organism or an engineered cardiomyocyte or a plurality of engineered cardiomyocytes, and wherein at least one organoid cartridge comprises cardiomyocytes of a diseased organism or engineered cardiomyocytes; and

(ii) a detection device for observing the monitored biological development of the cardiomyocytes of the diseased organism or the engineered cardiomyocytes in each organoid cartridge.

22. The system of claim 21 , wherein the cardiomyocytes are engineered cardiomyocytes or are derived from a patient having Friedreich's ataxia (FRDA), Kearns-Sayre syndrome, carbohydrate-deficient glycoprotein syndrome type Ia, spinocerebellar ataxia, Wilson disease, Dandy-Walker syndrome, dilated cardiomyopathy with ataxia, Leigh disease, MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), or MERRF (myoclonic epilepsy with ragged red fibers).

23. The system of claim 21 , wherein the cardiomyocytes are engineered to have low frataxin (FXN) expression or are derived from a patient with Friedreich's ataxia (FRDA).

24. The system of claim 21 , wherein the microfabricated substrate comprises grooves oriented along a single axis of the substrate.

25. The system of claim 21 , wherein the electrical power source is at least one electrode or at least one electrified portion of the substrate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2022
From: NOVOHEART LIMITED
To: NOVOHEART INTERNATIONAL LIMITED
Reel/Frame 060756/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2020
From: LI, RONALD A.; COSTA, KEVIN D.
To: NOVOHEART LIMITED
Reel/Frame 053945/0564 →
Continuity (2)
Provisional Application 62649468 · Mar 28, 2018
Related Publication 20210132043A1 · May 6, 2021
References Cited (65)
US 20130137132A1 · Dekker · 2013 [cited by examiner]
US 20140349332A1 · Yasuda et al. · 2014 [cited by applicant]
US 20150313704A1 · Thavandiran · 2015 [cited by examiner]
US 20160003806A1 · Parker · 2016 [cited by examiner]
US 20170107469A1 · Costa et al. · 2017 [cited by applicant]
WO 2010127280A1 · 2010 [cited by applicant]
WO 2014047387A2 · 2014 [cited by applicant]
WO 2015081226A1 · 2015 [cited by applicant]
WO 2016036532A1 · 2016 [cited by applicant]
WO 2016069142A2 · 2016 [cited by applicant]
WO 2017059171A1 · 2017 [cited by applicant]
WO 2018029535A1 · 2018 [cited by applicant]
Wilson et al., Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499, Circ. Cardiovasc Genet., 3:426-435 (2010). [cited by applicant]
Zhang et al., Consensus Comparative Analysis of Human Embryonic Stem Cell-Derived Cardiomyocytes, PLoS One, 10:e0125442 (2015). [cited by applicant]
Zhuo Z., Laser interference testing technology and applications, Machinery Industry Press, pp. 52-53, Oct. 1998. [cited by applicant]
Al-Mahdawi et al., Gaa repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology, Genomics, 88:580-590 (2006). [cited by applicant]
Casazza et al., The varying evolution of Friedreich's ataxia cardiomyopathy, Am. J. Cardiol., 77:895-898 (1996). [cited by applicant]
Cashman et al., Construction of defined human engineered cardiac tissues to study mechanisms of cardiac cell therapy, J. Vis. Exp., 109:e53447 (2016). [cited by applicant]
Chan et al., Label-free separation of human embryonic stem cells and their cardiac derivatives using Raman spectroscopy, Anal. Cham., 81:1324-1331 (2009). [cited by applicant]
Chen et al., Phospholamban as a Crucial Determinant of the Inotropic Response of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes and Engineered 3-Dimensional Tissue Constructs, Circ. Arrthyhm. Electrophys… [cited by applicant]
Chen et al., Shrink-film configurable multiscale wrinkles for functional alignment of human embryonic stem cells and their cardiac derivatives, Adv. Mater., 23:5785-5791 (2011). [cited by applicant]
Chow et al., Epigenetic regulation of the electrophysiological phenotype of human embryonic stem cell-derived ventricular cardiomyocytes: insights for driven maturation and hypertrophic growth, Stem Cells Dev., 22:2678-… [cited by applicant]
Dixon et al., The role of iron and reactive oxygen species in cell death, Nat. Chem. Biol., 10:9-17 (2014). [cited by applicant]
Durr et al., Clinical and genetic abnormalities in patients with Friedreich's ataxia, N. Engl. J. Med., 335:1169-1175 (1996). [cited by applicant]
Edenharter et al., Overexpression of [cited by applicant]
European Application No. 19774875.9, European Search Report and Opinion, mailed Dec. 14, 2021. [cited by applicant]
Filla et al., The relationship between trinucleotide (gaa) repeat length and clinical features in Friedreich ataxia, Am. J. Hum. Genet., 59:554-560 (1996). [cited by applicant]
Fu et al., Distinct roles of microRNA-1 and -499 in vent1icular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes, PLoS One, 6:e27417 (2011). [cited by applicant]
Fu et al., Na+/Ca2+ exchanger is a determinant of excitation-contraction coupling in human embryonic stem cell-derived ventricular cardiomyocytes, Stem Cells Dev., 19:773-782 (2010). [cited by applicant]
Goffart et al., Regulation of mitochondrial proliferation in the heart: Power-plant failure contributes to cardiac failure in hypertrophy, Cardiovasc Res., 64(2):198-207 (2004). [cited by applicant]
Hick et al., Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia, Dis. Model Mech., 6:608-621 (2013). [cited by applicant]
International Application No. PCT/IB19/00498, International Preliminary Report on Patentability, mailed Oct. 8, 2020. [cited by applicant]
International Application No. PCT/IB19/00498, International Search Report and Written Opinion, mailed Nov. 13, 2019. [cited by applicant]
Isnard et al., Correlation between left ventricular hypertrophy and gaa trinucleotide repeat length in Friedreich's ataxia, Circulation, 95:2247-2249 (1997). [cited by applicant]
Karakikes et al., Correction of human phospholamban RI4del mutation associated with cardiomyopathy using targeted nucleases and combination therapy, Nat. Commun., 6:6955 (2015). [cited by applicant]
Karakikes et al., Small Molecule-Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes, Stem Cells Transl. Med., 3:18-31 (2014). [cited by applicant]
Keung et al., Non-cell autonomous cues for enhanced functionality of human embryonic stem cell-derived cardiomyocytes via maturation of sarcolemmal and mitochondrial KATP channels, Sci. Rep., 6:34154 (2016). [cited by applicant]
Kipps et al., The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood, Pediatr Cardiol., 30:306-310 (2009). [cited by applicant]
Lee et al., Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA, Int. J. Cardiol., 203:9… [cited by applicant]
Lee et al., Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells, Pflugers Arch., 466:1831-1844 (2014). [cited by applicant]
Li et al., Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells, Biomaterials, 163:116-127 (2018). [cited by applicant]
Li et al., Mechanistic basis of excitation-contraction coupling in human pluripotent stem cell-derived ventricular cardiomyocytes revealed by Ca2+ spark characteristics: Direct evidence of functional Ca2+-induced Ca2+ r… [cited by applicant]
Lieu et al., Absence of Transverse Tubules Contributes to Non-Uniform Ca2+ Wavefronts in Mouse and Human Embryonic Stem Cell-Derived Cardiomyocytes, Stem Cells Dev., 18:1493-1500 (2009). [cited by applicant]
Lieu et al., Mechanism-Based Facilitated Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes, Circ. Arrhythm. Electrophysiol., 6:191-201 (2013). [cited by applicant]
Liu et al., Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression, Am. J. Physiol. Cell Physiol., 297:C152-159 (2009). [cited by applicant]
Liu et al., Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation, Stem Cells., 12:3038-44 (2007). [cited by applicant]
Lopaschuk et al., Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation, J. Cardiovasc Pharmacol., 56:130-140 (2010). [cited by applicant]
Luna et al., Multiscale Biomimetic Topography for the Alignment of Neonatal and Embryonic Stem Cell-Derived Heart Cells, Tissue Eng Part C Methods, 17:579-588 (2011). [cited by applicant]
Lynch et al., Management and therapy for cardiomyopathy in Friedreich's ataxia, Expert Rev Cardiovasc Ther., 10:767-777 (2012). [cited by applicant]
Martelli et al., Dysregulation of cellular iron metabolism in Friedreich ataxia: From primary iron-sulfur cluster deficit to mitochondrial iron accumulation, Front. Pharmacol., 5:130 (2014). [cited by applicant]
Miranda et al., Frataxin knockin mouse, FEES Lett., 512:291-297 (2002). [cited by applicant]
Payne et al., Cardiomyopathy of Friedreich's ataxia: Use of mouse models to understand human disease and guide therapeutic development, Pediatr Cardiol., 32:366-378 (2011). [cited by applicant]
Poon et al., Proteomic Analysis of Human Pluripotent Stem Cell-Derived, Fetal, and Adult Ventricular Cardiomyocytes Reveals Pathways Crucial for Cardiac Metabolism and Maturation, Circ. Cardiovasc Genet., 8:427-436 (201… [cited by applicant]
Poon et al., Transcriptome-Guided Functional Analyses Reveal Novel Biological Properties and Regulatory Hierarchy of Human Embryonic Stem Cell-Derived Ventricular Cardiomyocytes Crucial for Maturation, PLoS One, 8:e7778… [cited by applicant]
Puccio et al., Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and fe-s enzyme deficiency followed by intramitochondrial iron deposits, Nat. Genet., 27:181-186 (2001). [cited by applicant]
Rajagopalan et al., Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia, Mov. Disord., 25:846-852 (2010). [cited by applicant]
Ramirez et al., Pathology of intercalated discs in Friedreich cardiomyopathy, J. Am. Coll. Cardiol., 66:1739-1740 (2015). [cited by applicant]
Shum et al., A micropatterned human pluripotent stem cell-based ventricular cardiac anisotropic sheet for visualizing drug-induced arrhythmogenicity, Adv. Mater., 29(1):1602448 (2017). [cited by applicant]
Tandon, N., et al., Electrical stimulation systems for cardiac tissue engineering, Nature Protocols, 4(2):155-173 (2009). [cited by applicant]
Tsou et al., Mortality in Friedreich ataxia, J. Neural. Sci., 307:46-49 (2011). [cited by applicant]
Turnbull et al., Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium, FASEB J., 28:644-654 (2014). [cited by applicant]
Wang et al., Effect of engineered anisotropy on the susceptibility of human pluripotent stem cell-derived ventricular cardiomyocytes to arrhythmias, Biomaterials, 34:8878-8886 (2013). [cited by applicant]
Wang et al., Electrophysiological properties of pluripotent human and mouse embryonic stem cells, Stem Cells, 23(10):1526-34 (2005). [cited by applicant]
Weidemann et al., The cardiomyopathy in Friedreich's ataxia—new biomarker for staging cardiac involvement, Int. J. Cardiol., 194:50-57 (2015). [cited by applicant]
Weng et al., A Simple, Cost-Effective but Highly Efficient System for Deriving Ventricular Cardiomyocytes from Human Pluripotent Stem Cells, Stem Cells Dev., 23:1704-1716 (2014). [cited by applicant]